The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia.
BCR signaling
CLL
biomarkers
immunoglobulin genes
transformation
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
09
2021
accepted:
02
12
2021
entrez:
7
1
2022
pubmed:
8
1
2022
medline:
8
1
2022
Statut:
epublish
Résumé
Advanced genome-wide association studies (GWAS) identified several transforming mutations in susceptible loci which are recognized as valuable prognostic markers in chronic lymphocytic leukemia (CLL) and B cell lymphoma (BCL). Alongside, robust genetic manipulations facilitated the generation of preclinical mouse models to validate mutations associated with poor prognosis and refractory B cell malignancies. Taken together, these studies identified new prognostic markers that could achieve characteristics of precision biomarkers for molecular diagnosis. On the contrary, the idea of augmented B cell antigen receptor (BCR) signaling as a transforming cue has somewhat receded despite the efficacy of Btk and Syk inhibitors. Recent studies from several research groups pointed out that acquired mutations in BCR components serve as faithful biomarkers, which become important for precision diagnostics and therapy, due to their relevant role in augmented BCR signaling and CLL pathogenesis. For example, we showed that expression of a single point mutated immunoglobulin light chain (LC) recombined through the variable gene segment IGLV3-21, named IGLV3-21
Identifiants
pubmed: 34993136
doi: 10.3389/fonc.2021.771669
pmc: PMC8724047
doi:
Types de publication
Journal Article
Langues
eng
Pagination
771669Informations de copyright
Copyright © 2021 Nicolò, Linder, Jumaa and Maity.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Proc Natl Acad Sci U S A. 2017 May 16;114(20):5231-5236
pubmed: 28461496
Front Immunol. 2021 Apr 12;12:627602
pubmed: 33912159
Nat Commun. 2019 Aug 9;10(1):3615
pubmed: 31399598
Genet Epidemiol. 2019 Oct;43(7):844-863
pubmed: 31407831
Hemasphere. 2020 Jan 22;4(1):e334
pubmed: 32382709
Leukemia. 2021 Jun;35(6):1610-1620
pubmed: 33087831
Blood. 2021 Mar 11;137(10):1365-1376
pubmed: 32992344
N Engl J Med. 2020 Jul 30;383(5):498-500
pubmed: 32726539
Cell Rep. 2019 Jul 23;28(4):923-937.e3
pubmed: 31340154
Haematologica. 2020 Jul 03;105(9):2205-2217
pubmed: 33054046
Nat Commun. 2021 Jan 28;12(1):665
pubmed: 33510140
Blood. 2017 Mar 16;129(11):1469-1479
pubmed: 28049639
Clin Cancer Res. 2018 Oct 15;24(20):5048-5057
pubmed: 29945996
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
Clin Pharmacol Ther. 2001 Mar;69(3):89-95
pubmed: 11240971
Blood. 2012 Dec 6;120(24):4802-11
pubmed: 23071276
Blood. 2021 Apr 8;137(14):1895-1904
pubmed: 33036024
Br J Haematol. 2021 Feb;192(3):e77-e81
pubmed: 33278845
Leukemia. 2016 Apr;30(4):833-43
pubmed: 26582643
Nature. 2018 Aug;560(7718):387-391
pubmed: 29925955
Blood. 2021 Jul 22;138(3):246-258
pubmed: 34292322
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Nat Med. 2016 Apr;22(4):379-87
pubmed: 26974310
Leukemia. 2017 Feb;31(2):282-291
pubmed: 27811850
Blood. 2021 May 27;137(21):2935-2946
pubmed: 33211804
Blood Adv. 2020 Dec 22;4(24):6106-6116
pubmed: 33351104
Expert Rev Hematol. 2008 Oct;1(1):51-61
pubmed: 19802369
Front Oncol. 2021 Nov 03;11:771454
pubmed: 34804974
Front Immunol. 2020 Dec 14;11:594841
pubmed: 33381116
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
J Immunol. 2014 Feb 1;192(3):1024-33
pubmed: 24376268
Blood. 2015 Nov 12;126(20):2265-73
pubmed: 26405224
Blood Cancer J. 2016 Jun 10;6:e434
pubmed: 27284738
Nat Commun. 2017 Jun 09;8:15746
pubmed: 28598442
Med Oncol. 2019 Aug 2;36(9):79
pubmed: 31375939
Blood. 2012 May 10;119(19):4467-75
pubmed: 22415752
Cancers (Basel). 2020 Mar 11;12(3):
pubmed: 32168755
Front Oncol. 2021 Aug 26;11:740083
pubmed: 34513715
Eur J Haematol. 2015 Mar;94(3):193-205
pubmed: 25080849
Br J Cancer. 2016 Apr 12;114(8):849-54
pubmed: 27031852
J Mol Diagn. 2020 Sep;22(9):1114-1125
pubmed: 32615167
Leuk Lymphoma. 2021 Oct 11;:1-11
pubmed: 34632935
Blood. 2015 Jan 29;125(5):856-9
pubmed: 25634617
Haematologica. 2021 Sep 01;106(9):2334-2344
pubmed: 32732361
Blood. 2014 Aug 14;124(7):1010-9
pubmed: 25006127
Haematologica. 2021 Mar 11;:
pubmed: 33691380
Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2911-E2919
pubmed: 28314854
Nat Rev Cancer. 2022 Jan;22(1):45-64
pubmed: 34663943
Genes Chromosomes Cancer. 2021 Apr;60(4):287-292
pubmed: 33277788
Blood. 2012 Nov 15;120(20):4191-6
pubmed: 22915640
Nat Rev Cancer. 2016 Mar;16(3):145-62
pubmed: 26911189
Leukemia. 2017 Jun;31(6):1340-1347
pubmed: 28074063
Immunity. 2007 Mar;26(3):323-33
pubmed: 17331747
Hematol Oncol. 2021 Feb;39(1):105-113
pubmed: 33078436
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4320-4327
pubmed: 32047037
Clin Epigenetics. 2017 May 30;9:57
pubmed: 28572861
Nat Commun. 2019 Feb 18;10(1):820
pubmed: 30778055
Front Oncol. 2021 May 25;11:640731
pubmed: 34113563
Sci Rep. 2017 Nov 2;7(1):14888
pubmed: 29097663
Mol Cell. 2010 Sep 24;39(6):873-85
pubmed: 20864035
Am J Hematol. 2019 Nov;94(11):1266-1287
pubmed: 31364186
Nat Commun. 2016 Mar 09;7:10933
pubmed: 26956414
Cancer Cell. 2019 Feb 11;35(2):283-296.e5
pubmed: 30712845
Front Genet. 2021 Aug 02;12:687813
pubmed: 34408770
Curr Opin HIV AIDS. 2010 Nov;5(6):463-6
pubmed: 20978388
Blood. 2016 Feb 25;127(8):1007-16
pubmed: 26675346
Adv Hematol. 2012;2012:524308
pubmed: 21941553
Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13447-54
pubmed: 26483459
Proc Natl Acad Sci U S A. 2016 May 17;113(20):5688-93
pubmed: 27155012
BMC Genomics. 2013 Mar 12;14:163
pubmed: 23496831
Nat Commun. 2017 Jul 28;8(1):153
pubmed: 28751718